Natural History of Tuberculosis: Duration and Fatality of Untreated Pulmonary Tuberculosis in HIV Negative Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The prognosis, specifically the case fatality and duration, of untreated tuberculosis is important as many patients are not correctly diagnosed and therefore receive inadequate or no treatment. Furthermore, duration and case fatality of tuberculosis are key parameters in interpreting epidemiological data. METHODOLOGY AND PRINCIPAL FINDINGS: To estimate the duration and case fatality of untreated pulmonary tuberculosis in HIV negative patients we reviewed studies from the pre-chemotherapy era. Untreated smear-positive tuberculosis among HIV negative individuals has a 10-year case fatality variously reported between 53% and 86%, with a weighted mean of 70%. Ten-year case fatality of culture-positive smear-negative tuberculosis was nowhere reported directly but can be indirectly estimated to be approximately 20%. The duration of tuberculosis from onset to cure or death is approximately 3 years and appears to be similar for smear-positive and smear-negative tuberculosis. CONCLUSIONS: Current models of untreated tuberculosis that assume a total duration of 2 years until self-cure or death underestimate the duration of disease by about one year, but their case fatality estimates of 70% for smear-positive and 20% for culture-positive smear-negative tuberculosis appear to be satisfactory.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Selection of papers. Flowchart schematically showing inclusion and exclusion of papers. Those marked with a * were excluded either because they were referred to at places in the text that did not discuss duration of tuberculosis, tuberculosis mortality, case fatality, life tables or natural history, or because the title indicated that the paper was not about one of these topics; ** for two of these, data were included to the extent mentioned by Berg [115] (see legend of Table 3).](https://figures.cochat.ai/paper-figures/8114c3bf70fd484d9fe91b2b4854751c/natural-history-of-tuberculosis-duration-and-fatality-of-untreated-pulmonary-figure-1.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the average duration until cure or death is 3 years for untreated patients with tuberculosis,25”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Growing Burden of Tuberculosis: Global Trends and Interactions With the HIV Epidemic
Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., Raviglione, M. C., & Dye, C. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.9.1009 · Cited by 2,553 · cited 2×
“a 70% CF, as used by WHO and others in their estimates of the burden of tuberculosis [27], seems a reasonable ballpark figure.”
BackgroundMethodSelf-citationTuberculosis and diabetes mellitus: convergence of two epidemics
Dooley, K. E., & Chaisson, R. E. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70282-8 · Cited by 932 · cited 1×
“tuberculosis and progression to tuberculosis disease is influenced by host factors and especially risk of progression depends on the hosts’ immune status, which may be reduced due to concomitant HIV infection, diabetes, and other underlying diseases [27,28].”
BackgroundFluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review
Steingart, K. R., Henry, M., Ng, V., Hopewell, P. C., Ramsay, A., Cunningham, J., Urbanczik, R., Perkins, M., Aziz, M. A., & Pai, M. (2006) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(06)70578-3 · Cited by 798 · cited 1×
“smear, with low sensitivity for paucibacillary disease, is the only available diagnostic tool [6].”
BackgroundThe Competitive Cost of Antibiotic Resistance in Mycobacterium tuberculosis
Gagneux, S., Long, C. D., Small, P. M., Van, T., Schoolnik, G. K., & Bohannan, B. J. M. (2006) · Science · doi:10.1126/science.1124410 · Cited by 627 · cited 1×
“Furthermore, Mycobacterium tuberculosis strains resistant to rifampicin and INH might be less fit than drug susceptible strains and therefore lead to longer duration of disease with less mortality [15].”
BackgroundDye, C. (2005) · JAMA · doi:10.1001/jama.293.22.2767 · Cited by 534 · cited 1×
“course) strategy only offer free treatment to smear-positive cases in view of their disproportionate role in tuberculosis transmission and thus their large public health impact [7].”
BackgroundEspinal, M. A., Kim, S. J., Suarez, P. G., Kam, K. M., Khomenko, A. G., Migliori, G. B., Baéz, J., Kochi, A., Dye, C., & Raviglione, M. C. (2000) · JAMA · doi:10.1001/jama.283.19.2537 · Cited by 507 · cited 1×
“The prognosis of untreated tuberculosis is difficult to study these days as leaving patients untreated, especially in a study setting, is unethical. As an alternative, one could consider, as an approximation, the prognosis of multi-drug resistant (MDR) tuberculosis treated with first line drugs. However, MDR-tuberculo…”
HIV Infection and Multidrug‐Resistant Tuberculosis—The Perfect Storm
Wells, C. D., Cegielski, J. P., Nelson, L. J., Laserson, K. F., Holtz, T. H., Finlay, A., Castro, K. G., & Weyer, K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518665 · Cited by 483 · cited 4×
“As regards CF, the review of Payne and Bellamy [143] provided no information on the prognosis of HIV positive MDR-tuberculosis patients.”
BackgroundInfluentialTreatment of Tuberculosis in Patients with Advanced Human Immunodeficiency Virus Infection
Small, P. M., Schecter, G. F., Goodman, P. C., Sande, M. A., Chaisson, R. E., & Hopewell, P. C. (1991) · New England Journal of Medicine · doi:10.1056/nejm199101313240503 · Cited by 477 · cited 1×
“tuberculosis, of 16 months [145].”
The White Plague: Tuberculosis, Man and Society
(1954) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1954.tb85837.x · Cited by 388
Recurrence in tuberculosis: relapse or reinfection?
Lambert, M.-L., Hasker, E., Deun, A. V., Roberfroid, D., Boelaert, M., & Van der Stuyft, P. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00607-8 · Cited by 225 · cited 1×
“Moreover, of the two possible end points, cure is hard to measure, as relapses are common [140] and establishing cure in untreated tuberculosis patients requires extensive medical investigations.”
Background
Research works printed but not linked: 25
- JA Rutledge, 1919, The ultimate results in 1654 cases of tuberculosis treated at the modern Woodmen of America sanatorium., Am Rev Tuberc, 2, 755
- E Loewenstein, 1931, Die Zuchtung der Tuberkelbazillen aus dem stroemenden Blute., Zentralbl Bakteriol Parasitenkd Infektionskr Hyg, 1, 127
- KA Jensen, 1932, Reinzuchtung und Typenbestimmung von Tuberkelbazillenstammen., Zentralb Bakteriol Parasitenkd Infektionskr Hyg Abt, 1, 222
- GH Hamel, 1928, Jahresversammlung des Deutschen Zentral-komitees zur Bekämpfung der Tuberkulose. Erster Verhandlungstag. (discussions during annual meeting of the German Tuberculosis Control Committee)., Zeitschr Tuberk, 51, 497
- B Meidell, 1931, Die wahrscheinliche Lebensdauer und die Sterblichkeitsmessung., Skandinavisk aktuarietidskrift, 14, 217
- Anonymous, 1936, The expectation of life of the tuberculous., Tubercle, 17, 171
- F Oldenburg, 1931, Gedanken über das Schicksal offentuberkulöser Eisenbahner auf Grund statistischer Erhebungen., Zeitschr Tuberk, 61, 334
- S Phillips, 1964, Relapse in treated cases of pulmonary tuberculosis. II. Six-year follow-up of 109 patients discharged from the hospital with medical approval, 1955-1956., Am Rev Respir Dis, 90, 61
- W May, 1928, Welche Konsequenzen ergeben sich aus der Dauerstatistik der Heilverfahren bei Offentuberkulösen?, Zeitschr Tuberk, 51, 177
- H Ruge, 1909, Dauererfolge nach 10 Jahren bei Lungetuberkulose im Hochgebirge., Zeitsch Tuberk, 15, 146
- E Saegler, 1934, Beitrag zur Frage der Beziehungen zwischen Tuberkulose und Lebensalter., Zeitschr Tuberk, 71, 285
- E Stadler, 1903, Der Einfluss der Lungetuberkulose of Lebensdauer und Erwerbsfähigkeit und der Werth der Volksheilstättenbehandlung., Deutsch Arch Klin Med, 95, 412
- MG Stephens, 1941, Follow-up of 1041 tuberculous patients., Am Rev Tuberc, 44, 451
- PF Holst, 1906, Untersuchungen über die Lebensdauer der Schwindsüchtigen in Norwegen., Deutsch Arch Klin Med, 88, 325
- H Braeuning, 1920, Tuberkulöse Erkrankungen bei Schwestern infolge von Ansteckung im Dienst und ihre Verhütung., Zeitschr Tuberk, 33, 129
- AD De Besche, 1925, Dødeligheten av Lungentuberkulose i Oslo blandt til Byen indflyttede og der fødte Individer., Norsk Magazin for Laegevidenskaben, 86, 1229
- CRNF Van Joost, 1935, Opmerkingen naar aanleiding van een 200 tal met kunstmatige pneumothorax- en een 50 tal met middenrifsverlamming (phrenicusexairesis) behandelde gevallen van longtuberculose., Geneeskund Tijdschr v Ned Indië, 75, 1223
- B Van Vliet, 1963, Analyse van de sterfte aan longtuberculose te Amsterdam in de jaren 1960 en 1961., Ned Tijdschr Geneesk, 107, 2180
- SP Pamra, 1973, Changes in prevalence and incidence of pulmonary tuberculosis in Delhi in recent years., Ind J Tuberc, 20, 57
- CMF Sinding-Larsen, 1937, On the collapse treatment of pulmonary tuberculosis. A clinical adaption and follow-up examination of the material from Vejlefjord Sanatorium, 1906-1932., Acta Med Scand, 91, 39
- S Magnusson, 1938, Über den Verlauf und die Letalität der Tuberkulose in den verschiedenen Altersperioden., Acta Tuberc Scand, 12, 201
- W Münchbach, 1933, Das Schicksal des lungentuberkulösen Erwachsenen. Ergibnisse der Heilstattenbehandlung von annähernd 10000 Männern und Frauen., Tuberkulose-Bibliothek, 49, 64
- H Braeuning, 1936, Prognose der offenen Tuberkulose, Technik der Prognose-stellung und Rentabilität des Heilverfahrens., Zeitschr Tuberk, 75, 305
- H Braeuning, 1933, Die Prognose der offenen Lungentuberkulose., Tuberkulose-Bibliothek, 52, 40
- H Braeuning, 1930, Über die Letalität, Morbidität und Infektionsdauer der offenen Lungentuberkulose., Zeitschr Tuberk, 59, 109
Cited by
Items 201–300 of 630
Heterogeneous infectiousness in mathematical models of tuberculosis: A systematic review
Melsew, Y. A., Adekunle, A. I., Cheng, A. C., McBryde, E. S., Ragonnet, R. R., & Trauer, J. M. (2019) · Epidemics · doi:10.1016/j.epidem.2019.100374 · Cited by 14
Cost-effectiveness of rapid susceptibility testing against second-line drugs for tuberculosis
Dowdy, D. W., Hoog, A. H. V., Shah, M., & Cobelens, F. G. J. (2014) · The International Journal of Tuberculosis and Lung Disease · doi:10.5588/ijtld.13.0776 · Cited by 14
Murray, M. P., Cattamanchi, A., Denkinger, C. M., Hoog, A. H. V., Pai, M., & Dowdy, D. W. (2016) · BMJ Global Health · doi:10.1136/bmjgh-2016-000064 · Cited by 17
“At each month, the individual is assigned a probability of spontaneous resolution, death and returning to the health facility.(23) Those who return to the facility enter a similar decision algorithm (screening for”
BackgroundEtschmann, C., & Scherließ, R. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.121606 · Cited by 14
Pardeshi, G. S., DeLuca, A. N., Agarwal, S., & Kishore, J. (2018) · Tropical Medicine & International Health · doi:10.1111/tmi.13086 · Cited by 14
“Initial defaulters are infectious and experience high morbidity and mortality [20, 21].”
BackgroundTuberculosis Diagnoses Following Wildfire Smoke Exposure in California
Linde, L., Readhead, A., Barry, P. M., Balmes, J. R., & Lewnard, J. A. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202203-0457oc · Cited by 13
Wang, Y., Liu, Y., Long, M., Dong, Y., Li, L., & Zhou, X. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.09.026 · Cited by 14
Ramírez, L. M. N., Mehaffy, C., & Dobos, K. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1467016 · Cited by 15
Neglected diseases prioritized in Brazil under the perspective of metabolomics: A review
Canuto, G. A. B., da Cruz, P. L. R., Faccio, A. T., Klassen, A., & Tavares, M. F. M. (2015) · Electrophoresis · doi:10.1002/elps.201500102 · Cited by 16
Improving Control of Tuberculosis in Low-Burden Countries: Insights from Mathematical Modeling
White, P. J., & Abubakar, I. I. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.00394 · Cited by 13
“…link laboratory and surveillance data, and to link risk factors to outcomes (Baussano et al., 2006; Anderson et al., 2014; Stagg et al., 2015, 2016; Aldridge et al., 2016; Aldridge et al., in preparation); and systematic reviews (Tiemersma et al., 2011; Aldridge et al., 2014; Stagg et al., 2014).”
BackgroundJaved, S., Marsay, L., Wareham, A., Lewandowski, K. S., Williams, A., Dennis, M. J., Sharpe, S. A., Vipond, R., Silman, N. J., Ball, G., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154320 · Cited by 15
“Co-infection with HIV is common in low income countries and has a poor prognosis [3].”
Yang, C., Kang, J., Lu, L., Guo, X., Shen, X., Cohen, T., & Menzies, N. A. (2021) · BMC Medicine · doi:10.1186/s12916-021-01968-9 · Cited by 14
Gatti, D. M., Tyler, A. L., Mahoney, J. M., Churchill, G. A., Yener, B., Koyuncu, D., Gürcan, M. N., Niazi, M. K., Tavolara, T. E., Gower, A. C., et al. (2024) · PLoS Pathogens · doi:10.1371/journal.ppat.1011915 · Cited by 13
Wangari, I. M., Trauer, J. M., & Stone, L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206603 · Cited by 13
Machlaurin, A., Dolk, F. C. K., Setiawan, D., van der Werf, T. S., & Postma, M. J. (2020) · Vaccines · doi:10.3390/vaccines8040707 · Cited by 13
“03 [24] Untreated Patient Outcomes [25] calculated Dead 0.”
BackgroundMethodMathematical modelling of the progression of active tuberculosis: Insights from fluorography data
Avilov, K. K., Romanyukha, A. A., Belilovsky, E. M., & Borisov, S. E. (2022) · Infectious Disease Modelling · doi:10.1016/j.idm.2022.06.007 · Cited by 12
Kroidl, I., Ahmed, M. I. M., Horn, S., Polyak, C. S., Esber, A. L., Parikh, A. P., Eller, L. A., Kibuuka, H. N., Semwogerere, M., Mwesigwa, B., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101470 · Cited by 12
Vesga, J. F., Mohamed, M. S., Shandal, M., Jabbour, E. J., Lomtadze, N., Kubjane, M., Trajman, A., Meyer‐Rath, G., Avaliani, Z., Rotich, W., et al. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00321-3 · Cited by 12
Yuan, J., Wang, B., Chen, H., Lu, X. F., Sun, W. Y., Wang, D., Lu, J., Zhao, J., Zhang, C., & Xie, Y. (2015) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-015-5437-z · Cited by 13
Ngema, X. T., Baker, P., Ajayi, R. F., Aubert, P., & Banet, P. (2019) · Analytical Letters · doi:10.1080/00032719.2019.1636058 · Cited by 12
“This is particularly true in developing or poorer countries (Tiemersma et al. 2011) where the main methods used to predict or estimate TB incidence are based on case notifications (new and relapse TB cases notified in a given year) through expert opinion, prevalence survey through standard…”
BackgroundGaglani, P., Dwivedi, M., Upadhyay, T. K., Kaushal, R. S., Ahmad, I., & Saeed, M. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1152269 · Cited by 12
“Frontiers in Cellular and Infection Microbiology 02 observations of the TB disease without medication revealed that approximately 70% of those with positive sputum smear, pulmonary TB, and 20% of those with positive culture (but negative smear), pulmonary TB, faced death within 10 years of their diagnosis, respectivel…”
BackgroundAckley, S. F., Liu, F., Porco, T. C., & Pepperell, C. S. (2015) · PeerJ · doi:10.7717/peerj.1237 · Cited by 12
Prognostic Factors in Tuberculosis Related Mortalities in Hospitalized Patients
Haque, G., Kumar, A., Saifuddin, F., Ismail, S., Rizvi, N. A., Ghazal, S., & Notani, S. (2014) · Tuberculosis Research and Treatment · doi:10.1155/2014/624671 · Cited by 12
Worldwide Spatial and Temporal Distribution of Tuberculosis (TB)
Woldeyohannes, S. M. (2015) · Journal of AIDS & Clinical Research · doi:10.4172/2155-6113.1000452 · Cited by 12
N’Diaye, D. S., Nsengiyumva, N. P., Uppal, A., Oxlade, O., Alvarez, G. G., & Schwartzman, K. (2019) · BMC Medicine · doi:10.1186/s12916-019-1261-5 · Cited by 12
Han, W. M., Mahikul, W., Pouplin, T., Lawpoolsri, S., White, L. J., & Ngum, W. P. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248846 · Cited by 12
“1–2 Log-normal [52] Mortality rate on TB treatment 0.”
BackgroundFoster, N., Cunnama, L., McCarthy, K., Ramma, L., Siapka, M., Sinanovic, E., Churchyard, G., Fielding, K., Grant, A. D., & Cleary, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0251547 · Cited by 14
The Microbiome as Part of the Contemporary View of Tuberculosis Disease
Barbosa-Amezcua, M., Galeana-Cadena, D., Alvarado-Peña, N., & Silva‐Herzog, E. (2022) · Pathogens · doi:10.3390/pathogens11050584 · Cited by 17
“Studies in patients with pulmonary TB, and positive smear microscopy, prior to the advent of anti-TB drugs, were followed up for five years: 50–60% died; 20–25% were cured spontaneously; and 10–25% continued with symptoms of TB [38].”
BackgroundKim, H., Lee, Y. J., Song, M. J., Kwon, B. S., Kim, Y. W., Lim, S. Y., Lee, Y. J., Park, J. S., Cho, Y., Lee, C., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-38394-1 · Cited by 12
Structure–Function Analysis of the Essential Mycobacterium tuberculosis P450 Drug Target, CYP121A1
Padayachee, T., Lamb, D. C., Nelson, D. R., & Syed, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094886 · Cited by 11
“Without treatment, the death rate from TB disease is high (about 50% mortality) [2].”
BackgroundMacPherson, P., Stagg, H. R., Schwalb, A., Henderson, H., Taylor, A., Burke, R. M., Rickman, H. M., Miller, C. R., Houben, R. M. G. J., Dodd, P. J., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004448 · Cited by 11
Sex-related absolute inequalities in tuberculosis incidence in 47 countries in Africa
Mohammed, A., Aboagye, R. G., Duodu, P. A., Adnani, Q. E. S., Wongnaah, F. G., Seidu, A., & Ahinkorah, B. O. (2025) · BMC Medicine · doi:10.1186/s12916-025-04098-8 · Cited by 12
“Without treat-ment, about half of the people affected by TB may die [3, 9].”
Compliance and illiteracy when treating tuberculosis
Sveinbjörnsdóttir, G. M., Kamowa, D., Katundu, P. N., & Gizurarson, S. S. (2023) · International Health · doi:10.1093/inthealth/ihad077 · Cited by 11
Starshinova, A. A., Osipov, N. N., Dovgalyk, I., Kulpina, A., Belyaeva, E. N., & Kudlay, D. A. (2024) · Diagnostics · doi:10.3390/diagnostics14070698 · Cited by 13
“An approximate estimation showed that about 90% of people infected by M. tb are adults [5,6].”
BackgroundAndrews, J. R., Lawn, S. D., Dowdy, D. W., & Walensky, R. P. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit412 · Cited by 11
“provide insight on the survival of individuals with untreated tuberculosis [32].”
BackgroundLv, D., Liu, Y., Guo, F., Wu, A., Mo, Y., Wang, S., & Chu, J. (2020) · Journal of International Medical Research · doi:10.1177/0300060520925660 · Cited by 11
“A systematic review conducted in 2011 found that about 70% of patients with sputum smear-positive pulmonary tuberculosis died within 10 years of infection without appropriate drug treatment.(2) MTB represents a significant public health challenge in China because of poverty, delayed diagnosis and development of multi-…”
BackgroundTuberculosis sanatorium treatment at the advent of the chemotherapy era
Zwick, E. D., & Pepperell, C. S. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05539-w · Cited by 12
“Hospitalization typically lasted until self-cure or death, which could take years [5].”
BackgroundInfluentialPark, J. H., Koo, B., Kim, M. J., Lee, H. J., Cha, H.-H., Kim, J. Y., Lee, S. W., Shin, Y. M., & Kim, S. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1963839 · Cited by 11
“However, we could not rule out the possibility that these patients were recovered spontaneously without anti-TB treatment [21,22].”
BackgroundPando, C., Hazel, A., Tsang, L. Y., Razafindrina, K., Andriamiadanarivo, A., Rabetombosoa, R. M., Ambinintsoa, I., Sadananda, G. B., Small, P. M., Knoblauch, A. M., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-16425-w · Cited by 11
“Recovered cases have an 80% protection against reinfection [23].”
BackgroundEssawy, T. S., Saeed, A. M., & Fouad, N. A. (2014) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2014.01.001 · Cited by 11
Transmission modeling and health systems: the case of TB in India
Mandal, S., & Arinaminpathy, N. (2015) · International Health · doi:10.1093/inthealth/ihv004 · Cited by 11
Risk factors for tuberculosis mortality in a tertiary care center in Oman, 2006–2016
Gaifer, Z. (2017) · International Journal of Mycobacteriology · doi:10.4103/ijmy.ijmy_123_17 · Cited by 11
“Poor outcomes in TB patients were often attributed to host factors, mycobacterial microbial factors, and inappropriate TB treatment.[6,7] Delays in TB treatment may occur if patients seek medical advice late or if the health-care providers do not recognize the TB diagnosis.”
BackgroundAltes, H. K., Kloet, S., Cobelens, F. G. J., & Bootsma, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0192282 · Cited by 11
“25 (6, 21) triangular Death rate PTB δ1 /year 0.”
BackgroundHaines, I. E., & Lowenthal, R. M. (2011) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2011.02686.x · Cited by 10
Bayesian Evidence Synthesis to Estimate Subnational TB Incidence: An Application in Brazil
Chitwood, M. H., Pelissari, D. M., da Silva, G. D. M., Bartholomay, P., Rocha, M. S., Sanchez, M. N., Arakaki-Sánchez, D., Glaziou, P., Cohen, T., Castro, M. C., et al. (2019) · Epidemics · doi:10.1016/j.epidem.2021.100443 · Cited by 10
Kendall, E. A., Hussain, H., Kunkel, A., Kubiak, R. W., Trajman, A., Menzies, R., & Drain, P. K. (2021) · BMC Medicine · doi:10.1186/s12916-021-02189-w · Cited by 10
Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis
Vesga, J. F., Lienhardt, C., Nsengiyumva, P., Campbell, J. R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G., & Arinaminpathy, N. (2022) · BMC Medicine · doi:10.1186/s12916-022-02378-1 · Cited by 11
Peptenatu, D., Băloi, A., Andronic, O., Bolocan, A., Cioran, N., Gruia, A. K., Grecu, A., Panciu, T. C., Georgescu, L., Munteanu, I., et al. (2024) · GeoHealth · doi:10.1029/2023gh000972 · Cited by 10
Kyu, H. H., Ledesma, J. R., & Murray, C. J. L. (2024) · International Journal of Epidemiology · doi:10.1093/ije/dyae122 · Cited by 10
The identification of essential cellular genes is critical for validating drug targets
Xu, T., Wang, S., Ma, T., Dong, Y., Ashby, C. R., & Hao, G. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104215 · Cited by 10
Cost-effectiveness of incorporating bedaquiline into a treatment regimen for MDR/XDR-TB in Germany
Wolfson, L. J., Gibbert, J., Wirth, D., & Diel, R. (2015) · European Respiratory Journal · doi:10.1183/13993003.00811-2015 · Cited by 10
Estimating and Comparing Health and Financial Risk Protection Outcomes in Economic Evaluations
Verguet, S., & Norheim, O. F. (2021) · Value in Health · doi:10.1016/j.jval.2021.08.004 · Cited by 10
Comparison and lessons learned from neglected tropical diseases and tuberculosis
Wang, A., MacNeil, A., & Maloney, S. A. (2021) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000027 · Cited by 10
“Globally in 2018, the case fatality ratio of TB was 15%; however, if left untreated, in a 10-year time horizon, TB has a mortality rate of about 70% of patients with acid-fast bacillus (AFB) smear-positive results and 20% for those with AFB smear-negative results [13, 14].”
BackgroundDash, M., & BEHERA, B. P. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1015_21 · Cited by 10
“Treatment for people with rifampicin‐resistant TB (RR‐TB) and multidrug‐resistant TB (MDR‐TB) is longer, and requires drugs that are more expensive and more toxic.[8]”
BackgroundAcuña-Villaorduña, C., Ayakaka, I., Dryden‐Peterson, S., Nakubulwa, S. K., Worodria, W. O., Reilly, N., Hosford, J., Fennelly, K. P., Okwera, A., & Jones‐López, E. C. (2015) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0810 · Cited by 10
“Although the mortality rate is surprisingly high, it is consistent with previous studies in sub-Saharan Africa,6 long-term projections from our parent prospective study at this site,1 and a recent meta-analysis on the natural history of TB.8 We suspect the high mortality observed was related to the combination of drug…”
ResultThe Risk of Tuberculosis Infection in Non-dialysis Chronic Kidney Disease Patients
Li, C.-H., Chen, H.-J., Chen, W., Tu, C., Hsia, T., Hsu, W., Chang, C., Huang, C., BAU, D.-T., & Chou, C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.715010 · Cited by 10
Cardona, P.-J., Català, M., & Prats, C. (2022) · Pathogens · doi:10.3390/pathogens11030366 · Cited by 12
“In that case we based our assumptions on the data from a systematic review of the evolution of TB cases from the prechemotherapy era [41].”
MethodChopra, F., Eisenhauer, P., Falk, A., & Graeber, T. W. (2024) · American Economic Journal Microeconomics · doi:10.1257/mic.20210319 · Cited by 14
Empowering Tuberculosis Screening with Explainable Self-Supervised Deep Neural Networks
Patel, N., Wong, A. K. C., & Ebadi, A. (2024) · International Conference on Machine Learning and Applications · doi:10.1109/icmla61862.2024.00113 · Cited by 10
“Although tuberculosis is treatable, with about 85% of infections effectively cured using a six-month antibiotic regimen [4], the mortality rate from untreated TB disease remains notably high at around 50% [5].”
Can, M. H., Sweeney, S., Allwood, B., Dorman, S. E., Cohen, T., & Menzies, N. A. (2025) · The Lancet Global Health · doi:10.1016/s2214-109x(25)00114-7 · Cited by 9
Understanding the key challenges in tuberculosis drug discovery: what does the future hold?
Zein-Eddine, R., Ramuz, M., Refrégier, G., Lutzeyer, J. F., Aleksandrov, A. V., & Myllykallio, H. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2531229 · Cited by 11
“Without treatment, TB has a high mortality rate, nearing 50% [3].”
Post-tuberculosis lung disease: a guide for clinicians
Fumagalli, G., Mencarini, J., Sini, I., Allavena, L., Tadolini, M., Mantero, M., Blasi, F., Riccardi, N., Pontarelli, A., Piccioni, P., et al. (2025) · Infection · doi:10.1007/s15010-025-02645-2 · Cited by 9
Hepatoprotective Effect of Calotropis procera in Isoniazid and Rifampicin Induced Hepatotoxicity
Kamil, N. R., & Imran-ul-Haque, H. S. (2014) · Pharmacognosy Journal · doi:10.5530/pj.2014.5.3 · Cited by 9
Tuberculosis: Molecular Basis of Pathogenesis
Salvatore, P. P., & Zhang, Y. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95697-6 · Cited by 10
Yu, W., Wang, Y., Mei, J., Hu, F.-X., & Ji, L. (2019) · Springer eBooks · doi:10.1007/978-981-32-9763-0_1 · Cited by 9
Regan, M. C., Li, Y., Swartwood, N. A., Barham, T., Asay, G. R. B., Cohen, T., Hill, A. N., Horsburgh, C. R., Khan, A., Marks, S. M., et al. (2024) · The Lancet Public Health · doi:10.1016/s2468-2667(23)00276-1 · Cited by 10
Chen, G., Shen, L., Hu, H., Feng, Y., Wen, D., Liu, Y., Zhai, H., Sun, W., Wang, M., Lei, X., et al. (2024) · Microorganisms · doi:10.3390/microorganisms12061191 · Cited by 9
“The mortality rate among untreated TB patients reaches approximately 50% [5].”
BackgroundUsing the TIME model in Spectrum to estimate tuberculosis–HIV incidence and mortality
Pretorius, C., Glaziou, P., Dodd, P. J., White, R. G., & Houben, R. M. G. J. (2014) · AIDS · doi:10.1097/qad.0000000000000484 · Cited by 9
“For CFR values in HIV-negative tuberculosis cases and HIV-positive tuberculosis cases not on ART systematic reviews of prechemotherapy and pre-ART data, respectively, were used [20–22], as well as existing WHO estimates [1].”
MethodLiang, L., Ma, Y., Liu, X., & Lv, Y. (2017) · Springer eBooks · doi:10.1007/978-3-319-48683-3_8 · Cited by 9
on behalf of the Trial Team, Gao, M., Gao, J., Du, J., Liu, Y., Zhang, Y., Ma, L., Mi, F., Li, L., & Tang, S. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2505-7 · Cited by 9
MVA85A vaccine to enhance BCG for preventing tuberculosis
Kashangura, R., Jullien, S., Garner, P., Young, T., & Johnson, S. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012915 · Cited by 9
Tuberculosis treatment outcomes among precarious patients in France
Mechai, F., Bachelet, D., Han, L., Dubert, M., Parisey, M., Cordel, H., Bourgarit, A., Bertrac, C., Chauveau, S., Billard‐Pomares, T., et al. (2022) · Infectious Diseases Now · doi:10.1016/j.idnow.2022.08.004 · Cited by 9
Secular Trends in Tuberculosis during the Second Epidemiological Transition: A Swiss Perspective
Holloway‐Kew, K. L., Henneberg, R. J., Lopes, M. D. B., Staub, K., Link, K., Rühli, F. J., & Henneberg, M. (2013) · Advances in Anthropology · doi:10.4236/aa.2013.32011 · Cited by 10
Suggestive criteria for pulmonary tuberculosis in developing countries
Bregani, E. R., Valcarenghi, C., Tien, T. V., & Monzani, V. (2013) · International Journal of Mycobacteriology · doi:10.1016/j.ijmyco.2013.08.004 · Cited by 9
Kasaie, P., Mathema, B., Kelton, W. D., Azman, A. S., Pennington, J., & Dowdy, D. W. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144137 · Cited by 9
Strategic investment in tuberculosis control in the Republic of Bulgaria
Doan, T. N., Varleva, T., Zamfirova, M., Tyufekchieva, M., Keshelava, A., Hristov, K., Yaneva, A., Gadzheva, B., Zhang, S., Irbe, S., et al. (2019) · Epidemiology and Infection · doi:10.1017/s0950268819001857 · Cited by 9
“An untreated episode of active TB was assumed to last for three years, with a greater case fatality rate for smear-positive than for smear-negative and extrapulmonary TB (Supplementary Section 9) [14].”
BackgroundDrug-resistant tuberculosis: a new shot on goal
Nathan, C. (2014) · Nature Medicine · doi:10.1038/nm.3470 · Cited by 9
Kendall, E. A., Azman, A. S., Maartens, G., Boulle, A., Wilkinson, R. J., Dowdy, D. W., & Rangaka, M. X. (2018) · AIDS · doi:10.1097/qad.0000000000002053 · Cited by 9
“15 [39] TB-specific excess mortality rate (HIVþ, CD4þ <200, not on ART) 0.”
Riaz, S. M., Sviland, L., Hanevik, K., & Mustafa, T. (2024) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2024.102563 · Cited by 8
Téllez-Navarrete, N. A., Romero-Tendilla, J., Morales, A. R., Becerril, E., Alvarado-Peña, N., Salazar-Lezama, M. Á., Garciadiego-Fossas, P., Cadena-Torres, E., Chávez‐Galán, L., & Ramón‐Luing, L. A. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1505914 · Cited by 8
Samal, J., Preetha, G. S., & Singh, H. (2026) · Journal of the Egyptian Public Health Association · doi:10.1186/s42506-025-00204-z · Cited by 9
“Without treatment, the death rate from TB is high, at about 50% [3].”
The potential impact of vaccination on tuberculosis burden in India: A modelling analysis
Arinaminpathy, N., Rade, K., Kumar, R., Joshi, R. P., & Rao, R. (2023) · International Journal of Microbiology Research · doi:10.4103/ijmr.ijmr_328_23 · Cited by 8
Drug resistance in patients with tuberculous pleural effusions
Skouras, V. S., & Kalomenidis, I. (2018) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000483 · Cited by 8
“Without treatment, 70% of patients with smear-positive and 20% of those with smearnegative pulmonary TB die within 10 years from diagnosis [4].”
BackgroundHavumaki, J., Cohen, T., Zhai, C., Miller, J. C., Guikema, S. D., Eisenberg, M. C., & Zelner, J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008713 · Cited by 11
To protect or to kill: A persisting Darwinian immune dilemma
Besedovsky, H. O., & del Rey, A. (2022) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2022.04.019 · Cited by 8
Drug-Resistant Bone, Joint and Spine Tuberculosis: Evolution of Diagnosis and Treatment
Jain, A., Jain, P., Jaggi, K. R., Suresh, A., Yadav, M., Gain, A., & Gupta, H. (2024) · Indian Journal of Orthopaedics · doi:10.1007/s43465-024-01138-y · Cited by 8
“The prognosis of bone joint and spine TB was dismal with 50% of deaths in the pre-ATT era [2].”
Ssengooba, W., Nakiyingi, L., Armstrong, D. T., Cobelens, F. G. J., Alland, D., Manabe, Y. C., Dorman, S. E., Ellner, J. J., & Joloba, M. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107595 · Cited by 8
“it a better test for tuberculosis in individuals with HIV infection, who have high mortality if left untreated [34].”
BackgroundEconomic evaluations of point of care testing strategies for active tuberculosis
Zwerling, A. A., & Dowdy, D. W. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/erp.13.27 · Cited by 9
The Disease of the Italian Poet Giacomo Leopardi (1798–1837)
Sganzerla, E. P., & Riva, M. A. (2017) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000000534 · Cited by 8
The potential of imaging tools as correlates of infection and disease for new TB vaccine development
Malherbe, S. T., Kleynhans, L., & Walzl, G. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.06.001 · Cited by 8
Cilloni, L., Kranzer, K., Stagg, H. R., & Arinaminpathy, N. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003456 · Cited by 8
“0015 [38] Proportion of infections being ‘fast’ progressors to active disease pFast 0.”
BackgroundInfluentialUppal, A., Nsengiyumva, N. P., Signor, C., Louis, F. J., Rochette, M., Snowball, H., Etok, S., Annanack, D., Ikey, J., Khan, F. A., et al. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.210447 · Cited by 8
Woldesemayat, E. M., Datiko, D. G., & Lindtjørn, B. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116324 · Cited by 8
Linking Individual Natural History to Population Outcomes in Tuberculosis
Salvatore, P. P., Proaño, Á., Kendall, E. A., Gilman, R. H., & Dowdy, D. W. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix555 · Cited by 8
“We next define a conceptual “symptom threshold” as the disease burden above which active tuberculosis becomes symptomatic and clinically recognizable (ie, as would be observable in prechemotherapy studies of smear-positive tuberculosis patients) [17].”
BackgroundInfluentialKasaie, P., Pennington, J., Gupta, A., Dowdy, D. W., & Kendall, E. A. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciad557 · Cited by 7
Titan, A. V. L., Klaassen, F., Pelissari, D. M., Júnior, J. N. D. B. S., Alves, K. B. A., Alves, L. C., Sanchez, M. N., Bartholomay, P., Johansen, F. D. C., Croda, J., et al. (2024) · The Lancet Global Health · doi:10.1016/s2214-109x(24)00221-3 · Cited by 8
Rhines, A. S., Feldman, M. W., & Bendavid, E. (2018) · AIDS · doi:10.1097/qad.0000000000001959 · Cited by 7
Comparison Of Modeling Schemes for Natural Course Of Pulmonary Tuberculosis
Avilov, K. K., Romanyukha, A. A., Belilovsky, E. M., & Borisov, S. E. (2019) · Mathematical Biology and Bioinformatics · doi:10.17537/2019.14.570 · Cited by 7
Young, M., & Craig, J. (2020) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2020.101072 · Cited by 7
“servatively estimated to be around 3 years [11], and a single infectious case is estimated to potentially infect between 10 and 15 people in any given year.”
BackgroundTuberculosis in Mozambique: Where Do We Stand?
Nguenha, D., Manhiça, I., García‐Basteiro, A. L., & Cowan, J. (2018) · Current Tropical Medicine Reports · doi:10.1007/s40475-018-0167-1 · Cited by 7
Metadata
- Authors
- Tiemersma, E. W., van der Werf, M. J., Borgdorff, M. W., Williams, B. G., & Nagelkerke, N. J. D.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- GGD Amsterdam (NL)
- Stellenbosch University (ZA)
- United Arab Emirates University (AE)
- Corresponding author
- Tiemersma, Edine W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-04-04
- Volume
- 6
- Issue
- 4
- Pages
- e17601
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3070694
- OpenAlex
- W2138041013
- Cited by
- 583
- References
- 136
- Citations by year
- 2026: 33 · 2025: 53 · 2024: 46 · 2023: 48 · 2022: 40 · 2021: 36 · 2020: 38 · 2019: 39 · 2018: 43 · 2017: 42 · 2016: 35 · 2015: 43 · 2014: 39 · 2013: 31 · 2012: 10
- FWCI
- 3.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UvA-DARE (University of Amsterdam) (publishedVersion, other-oa)
- Pure Amsterdam UMC (publishedVersion)
- UvA-DARE (University of Amsterdam) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- World Health Organization
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Infectious Diseases › Infectious Diseases and Tuberculosis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › HIV, TB, and STIs Epidemiology
- Keywords
- case fatality, disease duration, HIV-negative patients, smear-positive tuberculosis, smear-negative tuberculosis, culture-positive tuberculosis, tuberculosis prognosis
- MeSH terms
- Humans, Time Factors, Tuberculosis, Pulmonary, Survival Analysis, HIV Seronegativity, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.